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Abstract Cerebral deposition of L-amyloid is a major neuro-
pathological feature in Alzheimer’s disease. Here we show that
tetracyclines, tetracycline and doxycycline, classical antibiotics,
exhibit anti-amyloidogenic activity. This capacity was deter-
mined by the exposure of L 1-42 amyloid peptide to the drugs
followed by the electron microscopy examination of the amyloid
fibrils spontaneously formed and quantified with thioflavine T
binding assay. The drugs reduced also the resistance of L 1-42
amyloid fibrils to trypsin digestion. Tetracyclines not only
inhibited the L-amyloid aggregates formation but also disas-
sembled the pre-formed fibrils. The results indicate that drugs
with a well-known clinical profile, including activity in the central
nervous system, are potentially useful for Alzheimer’s
therapy. ß 2001 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Alzheimer’s disease (AD) is the main cause of cognitive
decline and the third cause of death in the elderly. Despite
recent progress in the symptomatic therapy with cholinergic
drugs, we are still awaiting an e¡ective therapeutic approach
that interferes directly with the neurodegenerative process in
AD. AD is neuropathologically characterized by neuro¢bril-
lary tangles, an intracellular cytoskeletal alteration, and de-
posits of L-amyloid (AL) in the brain parenchyma and on the
wall of cerebral blood vessels.
The formation of AL deposits, which are insoluble ¢brils of
AL peptide 1-40 and 1-42, is an early event in AD and there
are now numerous genetic, biochemical and neuropathologi-
cal studies pointing to a causal role of AL in the pathogenesis
of AD [1]. The recent identi¢cation of an aspartyl-protease
responsible for AL synthesis might further help in clarifying
the essential role of AL [2]. According to the ‘amyloid cas-
cade’ hypothesis in AD [3] recently con¢rmed with neuropa-
thological examinations [4], prevention of the formation of AL
aggregates or their elimination once formed is a potential
therapeutic approach to the disease. We have found that io-
dodoxorubicin, an anthracycline with anti-tumoral activity,
inhibited the formation of amyloid aggregates in vitro and
in vivo [5^7]. The intrinsic toxicity and low blood^brain bar-
rier passage have inhibited the possibility of a direct use of
this drug in AD therapy. Based on some chemical analogies
with anthracyclines, we tested the anti-amyloidogenic capacity
of the antibiotic tetracycline, a molecule with a safety toxico-
logical pro¢le, whose derivatives (i.e. doxycycline) have a fa-
vorable distribution in the central nervous system (CNS) [8].
We investigated the anti-amyloidogenic capacity of tetracy-
cline and doxycycline using L 1-42 synthetic peptide, this pep-
tide is highly represented in AD amyloid deposits and has
been proposed as a seed molecule for amyloid formation. L
1-42 amyloid ¢brils spontaneously formed in vitro were ana-
lyzed by electron microscopy (EM). The anti-amyloidogenic
e¡ect was quanti¢ed by £uorescent thio£avine T binding to
amyloid structures. Since the self-aggregation capacity of L 1-
42 amyloid peptide is associated with a resistance to protease
digestion, we also tested whether tetracyclines facilitated the
hydrolysis of L 1-42 peptide by the proteolytic enzyme trypsin
[9].
2. Materials and methods
2.1. ‘Binding’ thio£avine T
The synthetic peptide LA 1-42 (Tecnogen, Caserta, Italy) was dis-
solved at a concentration of 0.22 mM in water:acetonitrile (1:1) and
aliquots of 30 Wg were lyophilized. The samples were dissolved in 30
Wl of Tris^HCl 100 mM, pH 7.4 and incubated for 5 days at 37‡C.
After a centrifugation for 10 min at 13 000Ug, the supernatant was
discharged and the pellet resuspended in 300 Wl of 50 mM glycine-
NaOH bu¡er, pH 9.6 including thio£avine T, 2 WM. The samples were
incubated for 5 min and the £uorescence was determined by a spec-
tro£uorimetric apparatus (LS 5OB Perkin Elmer Instr., Bekom¢eld,
UK) at the excitation and emission wavelengths of 420 and 480 nm,
respectively. The £uorescence values of the samples containing only
tested drug were determined and subtracted from the values of the
samples containing LA 1-42 ¢brils.
2.2. Protease digestion
After 5 days of incubation at 37‡C the solution of LA 1-42 in Tris^
HCl 100 mM, pH 7.4 was digested with trypsin (Merck, Darmstadt,
Germany) at 37‡C for 30 min at 1:120 (w/w) enzyme to substrate
ratio. After centrifugation at 13 000Ug for 10 min at 4‡C, the pellets
were dissolved in 80 Wl of 10% formic acid containing 0.1% tri£uoro-
acetic acid and analyzed by reverse-phase high performance liquid
chromatography (HPLC). Parallel samples were run in the absence
of tetracycline and analyzed as speci¢ed above with or without trypsin
digestion. The extent of proteolysis was calculated as the percentage
of peptide present in the pellet compared to the total amount origi-
nally present.
2.3. EM
The synthetic peptide LA 1-42 was suspended in 100 mM Tris^HCl,
pH 7.4, at a concentration of 0.22 mM either in the presence or in the
absence of an equimolar concentration of tetracycline. Following
5 days incubation at 37‡C, 5 Wl aliquots of peptide suspension were
applied to Formvar-coated nickel grids, negatively stained with 5%
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(w/v) uranyl acetate, and observed in an electron microscope (EM
109, Zeiss, Germany) at 80 kV.
3. Results
As shown in Fig. 1A, co-incubation of L 1-42 with tetracy-
cline for 5 days (Fig. 1B) markedly reduced the amyloid ¢brils
formation as detected by EM in comparison with the control
(Fig. 1A). This was con¢rmed by the measurement of speci¢c
binding of thio£avine T to amyloid ¢brils formed by L 1-42,
tetracyclines increasing ratios progressively reduced amyloid
formation (Fig. 1C). In similar conditions gentamicin and 4-
epianhydrotetracycline did not a¡ect thio£avine T binding
(data not shown). The inhibition of L 1-42 amyloid ¢brils
formation was associated with an increase of trypsin digestion
of the peptide, as shown in Fig. 2. The enzymatic degradation
of L 1-42 by trypsin was facilitated by the co-incubation with
tetracycline (Fig. 2A) or doxycycline (Fig. 2B) as determined
by HPLC analysis of residual peptide dissolved in formic acid/
tri£uoroacetic acid (9:1) solution. The HPLC determinations
showed an anti-amyloidogenic e¡ect of tetracyclines, without
trypsin, slightly inferior compared to the measure of thio£a-
vine T binding (Fig. 1C). This is likely due to the fact that
HPLC analysis identi¢ed the monomeric form of the peptide
deriving not only from ¢bers but also from oligomeric struc-
tures or non-amyloidogenic aggregates.
The tetracyclines not only inhibited the L 1-42 amyloid
aggregation but also exerted a de-¢brillogenic e¡ect against
pre-formed L 1-42 amyloid ¢brils. L 1-42 peptide was incu-
bated alone at 37‡C for 48 h and the tetracyclines were suc-
cessively added for an other 48 h, thio£avine T binding and
the resistance to trypsin were both reduced in relation to the
amount of drugs added (Fig. 3). At the maximal concentra-
tion the tetracyclines induce a complete degradation of L 1-42
exposed to trypsin (Fig. 2B). We also used £uorescent micros-
copy to analyze the speci¢c binding of tetracycline to L 1-42
Fig. 1. E¡ect of tetracyclines on the self-aggregation capacity of L 1-42 incubated for 5 days at 37‡C. Electron micrographies of L 1-42
(220 WM) ¢brils with (A) or without (B) equimolar concentration of tetracycline; in B the ¢brils disruption is evident. (C) Dose^response e¡ect
of tetracycline and doxycycline on thio£avine T binding to L 1-42 ¢brils spontaneously formed. The data are expressed as the percentage of
L 1-42 assayed without digestion. Mean þ S.E.M. of 10^12 replications. *P6 0.01 vs. respective control condition (Dunnett’s test). Bar = 100 nm.
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amyloid ¢brils in comparison with thio£avine T and the re-
sults con¢rmed the a⁄nity of tetracycline for amyloid struc-
tures (data not shown).
4. Discussion
Several substances, including endogenous compounds like
melatonin and laminin, have been found to inhibit the amy-
loid formation [10,11]. These compounds inhibit the ¢brillo-
genesis but their ability to dissolve pre-formed ¢brils has
never been shown. On the other hand short synthetic peptides,
designed as L-sheet breakers, inhibited amyloid formation and
disassemble pre-formed L 1-42 ¢brils [12] but several chemical
modi¢cations of the peptides structure will be necessary be-
fore obtaining derivatives suitable for clinical use. On the
contrary, tetracyclines are a well-know category of antibiotics
that include doxycycline and minocycline, used in clinical
practice for CNS injuries [13].
The selection of tetracycline as test compound was based on
structural analogies with Congo red and iododoxorubicin.
Although the molecular basis of tetracyclines anti-amyloido-
genic activity is not understood, it may be related to the
propensity of these drugs to bind the ¢brillogenic structure.
Like the anthracyclines, tetracyclines contain an extended hy-
drophobic core formed by aromatic moieties which permits
interactions with lipophilic residues of AL. A second charac-
teristic of these compounds is the presence of a variety of
polar substituents that can form hydrogen bonds with speci¢c
residues of AL, strengthening the drug to protein interaction.
Furthermore, the anti-amyloidogenic capacity of tetracyclines
is not exclusively against AL but it can also prevent and even
reverse the prion protein conformation changes associated
with spongiform encephalopathies that became sensitive to
protease degradation [14]. Tetracycline’s capacity to attenuate
the resistance of amyloid ¢brils to proteolysis is relevant for
the clearance of AL and to prevent the accumulation of the
peptide. As recently shown in experimental conditions [15] the
role of physiological catabolism of AL is essential for the
formation of cerebral amyloid deposition and a treatment,
like tetracyclines, that can facilitate the proteolytic degrada-
tion of AL is extremely useful. In terms of potential curative
intervention in AD, the capacity to disrupt pre-formed AL
aggregates exhibited by tetracyclines is also promising of e⁄-
cacy. It has recently been shown that an other derivative of
tetracycline, minocycline, exerted a neuroprotective e¡ect in a
transgenic model of Huntington disease [16]. This ¢nding con-
¢rms the blood^brain barrier passage and the curative e¡ect
of a tetracycline, independent from the antibiotic activity.
Furthermore, since the inhibition of caspase-1 and -3 expres-
sion has been proposed as potential mechanism responsible of
the minocycline e¡ect, this element could be favorable also in
Fig. 2. E¡ect of tetracyclines on the trypsin resistance of L 1-42 ¢-
brils. The presence of tetracycline (A) or doxycycline (B) progres-
sively reduced the partial resistance of L 1-42 digestion to trypsin.
The data are expressed as the percentage of L 1-42 assayed without
digestion. Mean þ S.E.M. of 10^12 replications. *P6 0.01 vs. respec-
tive control condition with trypsin. #P6 0.01 vs. control condition
without trypsin (Dunnett’s test).
Fig. 3. Disassembled e¡ect of tetracyclines on pre-formed L 1-42
amyloid ¢brils. L 1-42 (220 WM) was incubated at 37‡C for 48 h
alone (thio£avine T binding = 404.00 þ 12.25). Subsequently tetracy-
cline or doxycycline were added to the samples and the incubation
was continued for further 48 h, L 1-42 ¢brils were identi¢ed by
thio£avine T binding (A) or digested with trypsin (B) as explained
in the legend to Fig. 1. Mean þ S.E.M. of 10 replications. Ten^12
determinations, *P6 0.01 vs. respective control condition in A;
*P6 0.01 vs. respective control condition with trypsin, #P6 0.01 vs.
control condition without trypsin in B (Dunnett’s test).
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AD therapy. Thus, although in vivo studies will be necessary
to establish the e⁄cacy of the anti-amyloidogenic capacity of
tetracyclines, our data strongly suggest that these drugs might
o¡er a useful therapeutic approach to AD and other central
amyloidosis.
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